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Abstract
Background: Chronic Fatigue Syndrome, also known as Myalgic Encephalomyelitis (CFS/ME) is a debilitating
condition of unknown aetiology. It is characterized by a range of physiological effects including neurological,
sensory and motor disturbances. This study examined candidate genes for the above clinical manifestations to
identify single nucleotide polymorphism (SNP) alleles associated with CFS/ME compared with healthy controls.
Methods: DNA was extracted and whole genome genotyping was performed using the HumanOmniExpress
BeadChip array. Gene families for transient receptor potential ion channels, acetylcholine receptors, and adrenergic
receptors, and acetylcholinesterase were targeted. The frequency of each SNP and their association between CFS/
ME and healthy controls was examined using Fisher’s exact test, and to adjust for multiple testing, False Detection
Rate (FDR) and Bonferroni corrections were applied (p < 0.05).
Results: The study included 172 participants, consisting of 95 Fukuda defined CFS/ME patients (45.8 ± 8.9; 69 %
female) and 77 healthy controls (42.3 ± 10.3; 63 % female). A total of 950 SNPs were included for analysis. 60
significant SNPs were associated with CFS/ME compared with healthy controls. After applying FDR and Bonferroni
corrections, SNP rs2322333 in adrenergic receptor α1 (ADRA1A) was higher in CFS/ME compared with healthy
controls (45.3 % vs. 23.4 %; p = 0.059). The genotype class that was homozygous minor (AA) was substantially lower
in CFS/ME compared with healthy controls (4.2 % vs. 24.7 %).
Conclusions: This study reports for the first time the identification of ADRA1A and a possible association between
CFS/ME and genotype classes. Further examination of the functional role of this class of adrenergic receptors may
elucidate the cause of particular clinical manifestations observed in CFS/ME.
Keywords: Chronic fatigue syndrome, Myalgic encephalomyelitis, Genome association, Single nucleotide
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Background
Chronic Fatigue Syndrome, also referred to as Myalgic
Encephalomyelitis (CFS/ME) is an illness characterised
by chronic, debilitating fatigue that is not alleviated by
rest and accompanied by further symptoms. The
aetiology of CFS/ME remains unknown however it is as-
sociated with a range of physiological impairments in-
cluding neurological, immunological and autonomic
perturbations [1–3]. This includes cognitive difficulties,
short-term memory loss, pain, sleep disturbances, sensory
and motor disturbances, flu-like symptoms, gastrointes-
tinal disturbances, and autonomic symptoms [3]. More-
over, common infectious events prior to the onset of CFS/
ME include respiratory infections and gastrointestinal
illness [4].
Biological processes responsible for the varied symp-
toms reported for CFS/ME may involve several ion
channels and receptors that are located on cells through-
out the body. Transient receptor potential (TRP) ion
channels are widely expressed on tissues and cells and
are activated and regulated by various stimuli in the
cellular environment such as pain, temperature, taste,
pressure, and vision [5]. There are six TRP subfamilies:
ankyrin, canonical, melastatin, mucolipin, polycystin,
and TRPV [6]. Most consist of non-selective channels
permeable to cations such as calcium (Ca2+), sodium,
and magnesium. This cation permeability has an import-
ant role in maintaining homeostasis for a number of
physiological requirements. Accordingly, dysregulation of
these channels are found to have a role in pathological
conditions such as chronic pain, overactive bladder, dia-
betes, chronic obstructive pulmonary disease, cardiac
hypertrophy, familial Alzheimer’s disease, skin diseases,
skeletal dysplasias, neuropathy, and cancer [7–12].
In addition to TRP ion channels, acetylcholine receptors
(AChRs) are of particular interest due to their role in
neurological and neuromuscular transmission [13, 14].
AChRs may have a role in difficulties processing
information and short term memory loss reported in
CFS/ME [1, 15]. AChRs consist of two types that bind
with acetylcholine and transmit its signal. Nicotinic
AChRs (nAChRs) are ligand-gated ion channels and are
involved in fast synaptic interactions of neurotransmitters
[16]. Muscarinic AChRs (mAChRs) consist of 17 different
subunits and are G-protein coupled receptors that facili-
tate slow metabolic responses through secondary messen-
ger cascades [17].
Moreover, adrenergic receptors (ADRs) are another
class of G-protein coupled receptors which have
catecholamine ligands [18]. This binding is associated
with stimulation of the sympathetic nervous system,
commonly known for the fight or flight response in
which energy is mobilised and blood flow is diverted
from non-essential organs to skeletal muscle. There are
3 types of ADRs; Alpha 1 primarily involved in intracel-
lular Ca2+ and subsequent smooth muscle contractions
[19]. Alpha 2 receptors have a role in inhibition of neu-
rotransmitters, decreased cAMP and decreased smooth
muscle contraction. ß receptors increase cAMP activity
resulting in changes in heart muscle contractions,
smooth muscle relaxation and glycogenolysis [20, 21].
All three receptor types have three further subtypes [22].
Previously, we investigated SNPs and genotypes in TRPs
and AChRs in peripheral blood mononuclear cells in CFS/
ME patients compared with healthy controls [23, 24]. The
purpose of this current study was to identify whether fur-
ther SNPs in TRPs, AChRs, as well as for the first time,
ADRs have an association with CFS/ME patients com-
pared with healthy controls. As CFS/ME is largely charac-
terised as a heterogenous illness, this study served to
expand our investigation on the above ion channels and
receptors due to their wide expression in cells throughout




Participants were from the National Centre for Neuroim-
munology and Emerging Diseases (NCNED) research
database for CFS/ME. Participants aged between 18 and
65 years were recruited from community support net-
works in the South East Queensland and Northern New
South Wales region of Australia. All participants com-
pleted a screening questionnaire reporting their sociode-
mographic details, medical history, and symptoms. CFS/
ME patients were classified according to Fukuda criteria
[1]. This required the presence of fatigue that significantly
impacts with daily activities for at least 6 months. This
should not be due to ongoing exertion or other medical
conditions and accompanied by at least four of the follow-
ing symptoms: post-exertional malaise, unrefreshing sleep,
impairment of short-term memory or concentration,
muscle pain, joint pain, headaches, tender lymph nodes,
and/or sore throat. Healthy controls reported no evidence
of disease. Exclusions were participants not meeting the
above criteria or with other medical diagnoses that would
exclude CFS/ME for example autoimmune disorder, mul-
tiple sclerosis, psychosis, major depression, cardiovascular
disease. Participants were also excluded if they were preg-
nant, breast feeding, smokers or had a history of substance
abuse.
DNA extraction
Peripheral blood mononuclear cells were collected into
ethylenadiaminetetraacetic acid tubes. Routine pathology
was performed for screening of any abnormal parameters
including full blood count, erythrocyte sedimentation rate,
and high sensitivity C reactive protein by Pathology
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Queensland. The Qiagen DNA blood mini-kit was used to
extract approximately 2 μg of genomic DNA as per manu-
facturer instructions. To assess the quality and quantity of
DNA, the nCounter Digital Analyzer (Nanostring, United
States of America) optical scanner was used. Whole gen-
ome genotyping was performed using the HumanOm-
niExpress BeadChip array (Illumina, South Korea).
Statistical analysis
Statistical analysis was performed using PLINK v1.07
(http://pngu.mgh.harvard.edu/purcell/plink/) whole gen-
ome analysis software (Purcell, 2007) to identify the fre-
quency of SNPs. A principle component analysis was
performed to identify potential batch effect. For further
quality control, a major allele frequency filter of <1 %
was applied. Further, SNPs with an effect size variance
lower than 2 % were removed. Sample heterozygosity was
also applied as a quality control measure and calculated as
the proportion of heterozygous genotypes in relation to all
genotypes at the SNP and sample levels. Data were com-
pared between CFS/ME patients and healthy controls using
R (R Core Team, 2013). Fisher’s exact probability test was
used to examine significant genotype association for each in-
dividual SNP, and a Bonferroni correction for multiple test
correction was applied as post hoc analysis (p < 0.05).
Prediction analysis of significant SNPs
Prediction analysis of significant SNPs were performed
using Automated Splice Site and Exon Definition Ana-
lysis (http://splice.uwo.ca; ASSEDA). ASSEDA is a web
interface, which provides a tool to predict the effects of
sequence changes that alter mRNA splicing in human
disease. This tool is able to evaluate changes in splice
site strength based on theory-based modelling of donor
and acceptor splice sites [25].
Results
Demographic characteristics
The majority of participants in this study were of Caucasian
descent (97.8 %). Of the 172 participants, 95 met criteria for
CFS/ME and 77 met criteria for healthy controls, and the
mean age and proportion female was 45.8 ± 8.9 (69 %
female) and 42.3 ± 10.3 (63 % female) respectively. Potential
confounding factors for analysis such as age, sex and ethni-
city were analysed for interaction with genes of interest and
no outliers were identified, hence no adjustments were
required.
SNP association study
A total of 950 SNPs were included for analysis after
quality control measures were applied. The distribution
of these SNPs per chromosome is summarised in Fig. 1.
Accordingly, the majority of SNPs were observed on
chromosome 9 (204 SNPs).
Figure 2 demonstrates a Manhattan plot of results of
Fisher’s exact test. Blue line corresponds to the signifi-
cant threshold without any adjustment (raw p-values).
Prior to FDR and Bonferroni corrections, 60 significant
SNPs were associated with CFS/ME compared with
healthy controls. The red line corresponds to the signifi-
cant threshold after Bonferroni correction.
The raw p-values of the top 10 SNPs identified are
summarised in Table 1. The corresponding frequencies
in CFS/ME compared with healthy controls are shown.
Following adjustment applying FDR and Bonferroni
corrections, the association with alpha 1A ADR
(ADRA1A) SNP rs2322333 located on chromosome 8
was almost significant (p = 0.059). The proportion of
CFS/ME patients homozygous major (GG) for this SNP
was higher compared with healthy controls. Moreover,
the genotype class that was homozygous minor (AA)
Fig. 1 Frequency of SNPs per chromosome
Johnston et al. BMC Medical Genetics  (2016) 17:79 Page 3 of 7
was much lower in CFS/ME patients compared with
healthy controls (4.2 % vs. 24.7 %).
Prediction analysis
ASSEDA analysis predicted that a mutation of
rs2322333, located in the intronic and 3′UTR part of the
gene ADRA1A in chromosome 8, has a probability of
being deleterious with a ΔRi = −9.4, fold change = −32.7
and ΔZ = −2.8. This mutation leads to the abolition of
ELAV-like protein 1 (ELAVL1) binding site rs2695260.
Discussion
This study is the first to identify ADRA1A as a novel
candidate gene for CFS/ME. After stringent corrections
for multiple testing were applied, the ADRA1A SNP
remained predominant. Moreover, the proportion of pa-
tients that were homozygous minor, AA was much lower
in CFS/ME compared with healthy controls. These re-
sults particularly suggest that patients exhibiting this al-
lele marker may have a decreased risk of development of
CFS/ME.
The specific physiological implications of ADRA1A are
mainly involved in smooth muscle contraction [20]. This
is required for vasoconstriction of blood vessels through-
out the body including the skin, gastrointestinal system,
genitourinary system, kidney and brain. It is also involved
in the glycogenolysis and gluconeogenesis of adipose tis-
sue in the liver, in addition to enabling secretions from
sweat glands [26–29]. These above processes have been
associated with symptomatology of CFS/ME [3, 4]. Hence,
the differential expression of ADRA1A may explain par-
ticular clinical phenotypes of CFS/ME.
Alpha 1 ADRs are members of the superfamily for G
protein-coupled receptors [30]. When activated, hetero-
trimeric G protein (Gq/11) in turn activates phospholip-
ase (PLC). PLC cleaves phosphatidylinositol 4,5-
biphosphate, which leads to an increase in inositol tri-
phosphate (IP3) and diacylglycerol (DAG). IP3 acts as a
secondary messenger and is a soluble molecule that is
able to diffuse through the cytoplasm to the endoplas-
mic reticulum of cells (or sarcoplasmic reticulum in
muscle cells) to stimulate Ca2+ influx. This process in-
volves the binding of IP3 ligand to IP3 sensitive Ca
2+
channels that result in the release of Ca2+ into the cyto-
plasm [31, 32]. This mechanism contributes to a number
of cellular processes, including a slow after depolarizing
current (sADP) in neurons [33].
Of particular interest is the functional role of the SNP
rs2322333 identified in this study. ADRA1A is coded
from eleven variants where the SNP rs2322333 is located
in the 3′ untranslated region (3′-UTR) of two of these
variants, namely, ENST00000276393, ADRA1A-003 and
ENST00000380572 ADRA1A-005, while the remainder
are located in the intronic region of this gene (http://
ensembl.org). The 3′-UTR is a binding site for regula-
tory proteins, binding to specific sites within the 3′-UTR
may decrease gene expression of various mRNAs by ei-
ther inhibiting translation or directly causing degrad-
ation of the transcript. [34] Moreover, the allele AA for
rs2322333 may have a key role in ligand selectivity [22].
Through prediction analysis, this study identified that
mutation of rs2322333 in ADRA1A, results in the aboli-
tion of an RNA binding protein, ELAVL1. ELAVL1 is
known to bind to the 3′-UTR region of mRNAs to in-
crease stability [10–15]. A lack of these proteins can alter
the splicing of DNA, consequently changing protein ex-
pression by a change in isoforms. In particular, ELAVL1
has been found to bind with adenolate-uridylate rich ele-
ments (AREs) in c-fos mRNAs [12]. The c-fos mRNAs are
involved in several cellular processes that include cell pro-
liferation, survival and differentiation. It further has a role
in the physiological processes of oxygen deficiency in the
Fig. 2 Manhattan plot of Fisher’s exact test on 950 SNPs
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tissues (hypoxia) and the formation of new blood vessels
(angiogenesis) [16]. Hence, dysregulation of c-fos mRNAs
are known to have an important factor in cancer
development.
Furthermore, ELAVL1 bind with AREs in interleukin-3
(IL-3) mRNAs. IL-3 is an important cytokine that pro-
motes cell growth. It stimulates the differentiation of
hematopoietic stem cells into myeloid progenitor cells or
with IL-7, into lymphoid progenitor cells. In combination
with other cytokines IL-3 stimulates the proliferation of
all myeloid cells including granulocytes, monocytes, and
dendritic cells. In autoimmunity, IL-3 and other cytokines
are important for the proliferation of regulatory T cells
(Tregs) [17]. Dysfunction of Tregs has been reported in
immunological dysfunction of CFS/ME, in which FoxP3 se-
cretion by CD4+ T cells has been found to be significantly
higher in patients compared with healthy controls [18, 19].
Moreover, ELAVL1 with zinc finger protein 385A
(ZNF385A), another RNA-binding protein, can affect the
localization and translation of p53/TP53 mRNA. With
ZNF385A, ELAVL1 binds the 3′-UTR of p53/TP53
mRNA to control their nuclear export induced by cyclin
dependent kinase inhibitor 2A (CDKN2A), which is a pro-
tein coding gene. This may regulate p53/TP53 expression
and have a role in the mediation of CDKN2A anti-
proliferative activity. Accordingly, the dysregulation of
CDKN2A is associated with the development of a wide
variety of tumours. Alternatively, it may also regulate p53/
Table 1 Results of Fisher’s exact test for top 10 SNPs
Gene SNP name raw p-value padj FDR padj Bonferroni Genotype Controls allele frequency (%) Cases allele frequency (%) Odds ratios
ADRA1A rs2322333 6.2e-05 0.059 0.059 AA 19 4 0.08
AG 40 48 0.5
GG 18 43 1
TRPM1 rs4779824 0.002 0.788 1 CC 34 4 0.02
TC 39 51 0.26
TT 4 20 1
TRPM6 rs11787707 0.004 0.788 1 AA 54 84 1
AG 22 11 0.32
GG 1 0 0
TRPM1 rs10467996 0.005 0.788 1 CC 4 17 5.72
TC 34 49 1.94
TT 39 29 1
TRPM3 rs10118380 0.01 0.788 1 CC 8 21 3.39
TC 52 43 1.07
TT 31 24 1
TRPM3 rs7022747 0.013 0.788 1 AG 8 1 NA
GG 69 94 10.9
AA NA NA NA
CHRNB4 rs1316971 0.013 0.788 1 AA 10 0 0
AG 38 32 0.65
GG 46 60 0
ADRA1A rs526302 0.013 0.788 1 GG 39 63 1
TG 29 30 0.64
TT 9 2 0.14
TRPM8 rs6719311 0.013 0.788 1 AA 0 0 NA
AG 20 8 0.37
GG 68 74 NA
ADRA1A rs11782159 0.016 0.788 1 AA 29 21 1
AC 39 50 1.77
CC 9 24 3.68
Abbreviations: SNP single nucleotide polymorphism, padj adjusted p-value, FDR false detection rate, ADRA adrenergic receptor alpha, TRPM transient receptor potential
melastatin ion channel, CHRN cholinergic receptor nicotinic beta
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TP53 activity through direct protein-protein interaction.
This may promote cell-cycle arrest over apoptosis,
through preferential binding of DNA and transactivation
of p53/TP53 on cell-cycle arrest target genes over pro-
apoptotic target genes. It may also regulate the ubiquitina-
tion and stability of cyclin dependent kinase inhibitor 1A
(CDKN1A), which inhibits cellular proliferation in re-
sponse to DNA damage [20].
Physiologically, ADR subtypes are associated with nu-
merous systems including neurological, cardiovascular, re-
spiratory and urogenital systems. [27, 35] Alpha 1 ADRs
exert effects in hypothalamo-pituitary-adrenocortical
(HPA) axis, corticotropin releasing factor (CRF) and
behavioural stress responses [36]. Alpha 1 ADRs are
widely distributed in CNS including neurons, glial cells
and located in hypothalamic nuclei, brainstem and spinal
cord notably associated with motor function [36].
Alpha 1 ADRs are located in the nuclei of adult myocar-
dium cells and participates in intra-nuclear signalling [37].
These receptors regulate cardioprotective functions includ-
ing physiological hypertrophy, protection from apoptosis,
positive iontropy and preconditioning. Importantly alpha 1
ADRs rescue myocytes from cell death via an alpha 1A-ERK
signalling pathway. Rescue is mimicked by expression of
(mitogen activated protein kinase kinase) MEK which in-
creases (extracellular signal-related kinase) ERK activity [38].
We have recently reported significant changes in ERK1/2
and MEK 1/2 in isolated natural killer cells from CFS/ME
patients. Specifically, we reported a significant reduction in
ERK1/2 and also a significant increase in MEK1/2, suggest-
ing a dysregulation in MEK/ERK signalling not only in NK
cells but also conceivably in cardiac myocytes and other tis-
sues that have these receptors [39].
O’Connell et al. [40], also describe alpha 1 ADRs in nuclei
of human heart myocardium and their role in cardiac fail-
ure. These authors assert that these receptors have a
strongly cardioprotective role in prevention of cardiac myo-
cyte death through activation of ERK. Alpha 1 ADRs can
participate in myocardial contractile function both through
intrinsic inotropic effects as well as countering the negative
inotropic response mediated by other subtypes [41]. It is
likely that alpha 1 ADRs also participates in protection
from hypoxia. Compromise of function could potentially
contribute to adverse symptomatology associated with im-
paired neuroprotection resulting from chronic intermittent
hypobaric hypoxia (CIHH). CIHH increases the activity of
alpha 1 ADRs, which is possibly one of the mechanisms for
the cardioprotection of CIHH [42]. Importantly, the cardio-
vascular system in CFS/ME has been reported to be com-
promised as manifested by postural orthostatic tachycardia
syndrome, poor peripheral circulation, intolerance to phys-
ical exercise and poor cerebral perfusion and systemic per-
fusion [43–47]. Collectively, these symptoms and signs
suggest a clinical presentation of dysautonomia.
This study further expands our previous investigations
into TRPs, AChRs, and ADRs in CFS/ME. In particular,
it is the first genome association study on adrenergic re-
ceptors conducted on an Australian cohort with CFS/
ME. A particular strength of this study was the consider-
able association with ADRA1A gene found among a pre-
liminary cohort of patients, when strict statistical
considerations were applied. Further validation of this
and previous preliminary findings in TRPs and AChRs,
will be required in a replication study in a larger cohort
of patients. However, the present findings provide sup-
porting evidence for investigation into the role of adren-
ergic receptors in CFS/ME.
Conclusions
In conclusion, this study demonstrated that the
ADRA1A gene may be a potential cellular marker for
CFS/ME. It is recommended that future studies examine
the role of adrenergic genes and specifically their geno-
types to elucidate whether they have a potential protect-
ive role against CFS/ME.
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